Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (2): 521-529     DOI: 10.31083/j.rcm2202060
Special Issue: State-of-the-Art Cardiovascular Medicine in Asia 2021
Original Research Previous articles | Next articles
Prevalence and treatment of high cardiovascular disease risk in Inner Mongolia, China
Yunfeng Xi1, †, Ning Cao2, †, Liwei Niu2, Hao Zhu2, Han Bao2, Liying Qiao1, Shuqi Ji2, Tao Yan2, Xiaoqian Xu2, Wenrui Wang1, *(), Xingguang Zhang2, *()
1The Inner Mongolia Autonomous Region Comprehensive Center or Disease Control and Prevention, 010110 Hohhot, Inner Mongolia, China
2School of Public Health, Inner Mongolia Medical University, 010110 Hohhot, Inner Mongolia, China
Download:  PDF(916KB)  ( 305 ) Full text   ( 14 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Early identification of individuals with high risk is crucial to preventing cardiovascular disease (CVD). We aimed to determine the prevalence of high CVD risk in Inner Mongolia and to analyze the treatment of major risk factors among individuals with high CVD risk. We selected 70,380 participants aged 35–75 years in Inner Mongolia between 2015 and 2017 using multistage stratified sampling. All participants completed a questionnaire and their blood pressure, blood glucose and lipid levels, height, weight and waist circumference were measured. Participants without a history of CVD were defined as high CVD risk if the predicted 10-year risk for CVD exceeded 10%. We assessed rates of high CVD risk and the prevalence and treatment of major risk factors among individuals with high CVD risk. After excluding participants with previous CVD, 68,083 participants remained. The overall prevalence of high CVD risk was 24.96%. The age- and sex-standardized rate of high CVD risk was 22.92%. Among high-risk participants, the prevalence of risk factors was hypertension (91.9%), dyslipidemia (54.1%), obesity (34.6%), diabetes (27.6%), and smoking (24.5%); clustering of these risk factors was common. The percentage of high-risk individuals taking antihypertensive drugs was 45.94% in those with hypertension; 27.99% of those with diabetes took hypoglycemic drugs and only 5.01% of those with dyslipidemia took lipid-lowering drugs. Control rates of hypertension, diabetes, and dyslipidemia were 1.20%, 4.43%, and 2.78%, respectively. Therefore, the prevalence of high CVD risk was elevated in Inner Mongolia, and treatment and control rates were low.
Key words:  Epidemiology      Cardiovascular disease      High risk individuals     
Submitted:  14 April 2021      Revised:  21 May 2021      Accepted:  10 June 2021      Published:  30 June 2021     
Fund: 
Ministry of Finance of China and National Health and Family Planning Commission of China
201701041/Inner Mongolia Autonomous Region Health and Family Planning Commission Research Project
2020MS08048/Natural Science Foundation Program of Inner Mongolia Autonomous Region
YKD2020QNCX035/Youth Innovation Fund Project of Inner Mongolia Medical University
*Corresponding Author(s):  wr821@163.com (Wenrui Wang); zxg311@126.com (Xingguang Zhang)   
About author:  These authors contributed equally.

Cite this article: 

Yunfeng Xi, Ning Cao, Liwei Niu, Hao Zhu, Han Bao, Liying Qiao, Shuqi Ji, Tao Yan, Xiaoqian Xu, Wenrui Wang, Xingguang Zhang. Prevalence and treatment of high cardiovascular disease risk in Inner Mongolia, China. Reviews in Cardiovascular Medicine, 2021, 22(2): 521-529.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2202060     OR     https://rcm.imrpress.com/EN/Y2021/V22/I2/521

[1] Raffaele Galiero, Alfredo Caturano, Erica Vetrano, Arturo Cesaro, Luca Rinaldi, Teresa Salvatore, Raffaele Marfella, Celestino Sardu, Elisabetta Moscarella, Felice Gragnano, Paolo Calabrò, Ferdinando Carlo Sasso. Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 755-768.
[2] Xiaoqing Zhu, Guanhua Xu, Wangyan Jin, Yingying Gu, Xuhua Huang, Lidan Ge. Apple or apple polyphenol consumption improves cardiovascular disease risk factors: a systematic review and meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 835-843.
[3] Niki Katsiki, Matina Kouvari, Demosthenes B Panagiotakos, Claudio Borghi, Christina Chrysohoou, Dimitri P Mikhailidis, Christos Pitsavos. The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 991-1001.
[4] Janani Rangaswami. Closing gaps in the care of patients with heart-kidney disease: the time is now[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 257-258.
[5] Saeed Shoar, Waleed Ikram, Ahmed Ali Shah, Najam Farooq, Srikanth Gouni, Soheila Khavandi, Elsa Tabibzadeh, Siamak Khavandi. Non-high-density lipoprotein (non-HDL) cholesterol in adolescence as a predictor of atherosclerotic cardiovascular diseases in adulthood[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 295-299.
[6] Eyad Abuelgasim, Suleyman Shah, Biyaser Abuelgasim, Nikita Soni, Ashvin Thomas, Mustafa Elgasim, Amer Harky. Clinical overview of diabetes mellitus as a risk factor for cardiovascular death[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 301-314.
[7] Kui Huang, Xiao-Qin Wen, Ning Ren, Li Yang, Bo Gao. Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 461-467.
[8] Sheng-Li Du, Zeng-Qin Jia, Jiu-Chang Zhong, Le-Feng Wang. TRPC5 in cardiovascular diseases[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 127-135.
[9] Chia-Te Liao, Wei-Ting Chang, Wen-Liang Yu, Han Siong Toh. Management of acute cardiovascular events in patients with COVID-19[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 577-581.
[10] Kihyun Kim, Jong-Youn Kim, Eui-Young Choi, Hyuck-Moon Kwon, Se-Joong Rim. Prevalence and risk factors for secondary hypertension among young Korean men[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 627-634.
[11] Radwan Al Ali, Davor Vukadinović, Wasim Maziak, Lama Katmeh, Viktoria Schwarz, Felix Mahfoud, Ulrich Laufs, Michael Böhm. Cardiovascular effects of waterpipe smoking: a systematic review and meta-analysis[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 453-468.
[12] Peter A. McCullough, John Eidt, Janani Rangaswami, Edgar Lerma, James Tumlin, Kevin Wheelan, Nevin Katz, Norman E. Lepor, Kris Vijay, Sandeep Soman, Bhupinder Singh, Sean P. McCullough, Haley B. McCullough, Alberto Palazzuoli, Gaetano M. Ruocco, Claudio Ronco. Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 1-7.
[13] Michele Provenzano, Giuseppe Coppolino, Teresa Faga, Carlo Garofalo, Raffaele Serra, Michele Andreucci. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 209-220.
[14] Shanna J. Hardin, Mahavir Singh, Wintana Eyob, Jack C. Molnar, Rubens P. Homme, Akash K. George, Suresh C. Tyagi. Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 121-128.
[15] Wenyan Jiang, Mei Wang. New insights into the immunomodulatory role of exosomes in cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 153-160.
No Suggested Reading articles found!